Clinical Trials | March 11, 2026
Roche reports Phase III persevERA breast cancer trial results
Giredestrant shows promise despite missing primary goal
Giredestrant shows promise despite missing primary goal
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
